SciFluor Life Sciences, LLC

16 articles about SciFluor Life Sciences, LLC

• SciFluor Announces Appointment of Robert Dempsey to Board of Directors

  8/15/2018

  Dempsey brings deep knowledge of the Pharmaceutical Industry and Ophthalmology commercial experience to the Board of Directors.

• SciFluor Announces Positive Top-Line Results of Phase I/II Study of SF0166 Eye Drops to Treat Wet Age-Related Macular Degeneration

  12/18/2017

  SciFluor announced positive top-line results of a Phase 1/2 trial studying the treatment of ‘wet’ age-related macular degeneration (AMD) patients with SF0166, the company’s lead eye drop drug for back of the eye diseases.

• SciFluor Announces 6 New Patent Issuances Covering the Use of SF0166 Topical Ophthalmic Solution in Retinal Diseases

  12/12/2017

  This patent is supported by an additional 5 patents issued earlier by the U.S. Patent and Trademark Office (US 9,266,884, US 9,518,053, US 9,593,114, US 9,717,729, and US 9,802,933) which provide intellectual property protection for SF0166 and its analogs for composition of matter and methods of use through 2034.

• SciFluor Life Sciences, LLC Announces Positive Results Of Phase I/II Study Of SF0166 Topical Ophthalmic Solution In Diabetic Macular Edema Patients

  9/28/2017

• SciFluor Life Sciences, LLC Announces First Patients Dosed In Retinal Program With Investigational New Drug Application For SF0166 Topical Ophthalmic Solution

  10/17/2016

• SciFluor Life Sciences, LLC Enters Clinical Trial Stage For Novel Treatment For Retinal Diseases

  8/1/2016

• SciFluor Life Sciences, LLC Awarded Second U.S. Patent For Integrin avß3 (SF0166) Inhibitors Designed For The Topical Treatment Of Retinal Disease

  3/9/2016

• SciFluor Life Sciences, LLC Patented Compound SF0034 Highlighted In Research Published In The Journal Of Neuroscience

  6/19/2015

• SciFluor Life Sciences, LLC Locks In $30 Million and Taps Ex-Neurogen Corporation CEO as Chairman

  4/22/2015

• SciFluor Life Sciences, LLC Awarded U.S. Patent For KCNQ2/3 Activator Designed For Treatment Of Epilepsy And Related Neurological Disorders

  1/8/2015

• SciFluor Life Sciences, LLC Awarded U.S. Patent For Integrin avß3 Inhibitors Designed For The Topical Treatment Of Retinal Disease

  12/4/2014

• SciFluor Life Sciences, LLC Presents New Preclinical Data Highlighting Lead Program as a More Potent and Selective Treatment for Partial-Onset Seizure

  6/25/2013

• Members of SciFluor Life Sciences, LLC' Leadership Team Receive National Industry Recognition

  8/2/2012

• SciFluor Life Sciences, LLC Expands Senior Management Team with Key Appointments

  3/13/2012

• SciFluor Life Sciences, LLC Extends License with Harvard University, Secures Technology to Advance and Transform the Use of PET Imaging in Drug Discovery & Development

  2/29/2012

• SciFluor Life Sciences, LLC Appoints Life Sciences Executive Arthur Hiller as CEO

  6/29/2011